Endonovo Therapeutics annual r&d spending
2016
2017
2018
2019
2020
2021
Endonovo Therapeutics R&D Spending Growth & History (ENDV)
Endonovo Therapeutics's r&d spending was $0 for fiscal 2021.
View full Endonovo Therapeutics company overviewEndonovo Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2021 | 2021-12-31 | $0 | −$3,283 | — |
| 2020 | 2020-12-31 | $3,283 | −$149,843 | −97.86% |
| 2019 | 2019-12-31 | $153,126 | −$121,139 | −44.17% |
| 2018 | 2018-12-31 | $274,265 | $159,106 | +138.16% |
| 2017 | 2017-12-31 | $115,159 | $115,159 | — |
| 2016 | 2016-12-31 | $0 | — | — |
Endonovo Therapeutics quarterly r&d spending
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q4 2021 | 2021-12-31 | $0 | $0 | — |
| Q3 2021 | 2021-09-30 | $0 | $0 | — |
| Q2 2021 | 2021-06-30 | $0 | −$2,280 | — |
| Q1 2021 | 2021-03-31 | $0 | −$1,003 | — |
| Q4 2020 | 2020-12-31 | $0 | — | — |
| Q3 2020 | 2020-09-30 | $0 | −$34,708 | — |
| Q2 2020 | 2020-06-30 | $2,280 | — | — |
| Q1 2020 | 2020-03-31 | $1,003 | −$62,298 | −98.42% |
| Q3 2019 | 2019-09-30 | $34,708 | $29,470 | +562.62% |
| Q1 2019 | 2019-03-31 | $63,301 | −$50,807 | −44.53% |
| Q4 2018 | 2018-12-31 | $111,192 | $71,379 | +179.29% |
| Q3 2018 | 2018-09-30 | $5,238 | −$70,108 | −93.05% |
| Q2 2018 | 2018-06-30 | $43,727 | $43,727 | — |
| Q1 2018 | 2018-03-31 | $114,108 | $114,108 | — |
| Q4 2017 | 2017-12-31 | $39,813 | — | — |
| Q3 2017 | 2017-09-30 | $75,346 | — | — |
| Q2 2017 | 2017-06-30 | $0 | — | — |
| Q1 2017 | 2017-03-31 | $0 | — | — |
Endonovo Therapeutics r&d spending trends
Over the last five fiscal years, Endonovo Therapeutics's r&d spending increased from $0 to $0, a change of $0. The latest reported quarter, Q4 2021, shows $0.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Endonovo Therapeutics source filings ↗